Mia Scott, DO
Family Medicine · Denver, CONPI 1215019724
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 69.0% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $18,449 and has fallen 91.3% since, to $1,605 in 2025. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 543 payments — averaging $97.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$37K
- Gilead$9K
- Theratechnologies Inc.$4K
- Merck$949
- AbbVie$596
- Janssen Scientific Affairs, LLC$466
- plus $2K from 21 others
Across 147 payments — averaging $6395.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$508K
- Viiv Healthcare Company$398K
- Merck$33K
- GSK$828
What the payments were for
- Consulting fees$24,74047%
- Speaking & faculty fees$12,87524%
- Travel & lodging$1,4923%
- Food & beverage$14,03226%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 163 | $36,698 |
| Gilead | 185 | $9,282 |
| Theratechnologies Inc. | 9 | $3,560 |
| Merck | 48 | $949 |
| AbbVie(2 entities) | 40 | $596 |
| Janssen Scientific Affairs, LLC | 8 | $466 |
| Johnson & Johnson | 17 | $268 |
| Amarin Pharma, Inc. | 6 | $222 |
| Novo Nordisk | 9 | $211 |
| AstraZeneca | 11 | $149 |
| Lilly USA, LLC | 10 | $137 |
| Janssen Products, LP | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $108 |
| Antares Pharma, Inc. | 6 | $82 |
| Biohaven Pharmaceuticals, Inc. | 3 | $66 |
| Eisai Inc. | 3 | $47 |
| Dermira, Inc. | 2 | $38 |
| Dynavax Technologies Corporation | 5 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Neuronetics, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,187 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 151 | $597,255 |
| TivicayDolutegravir Sodium | 101 | $246,081 |
| DovatoDolutegravir Sodium/Lamivudine | 77 | $217,224 |
| RukobiaFostemsavir Tromethamine | 22 | $187,232 |
| DescovyEmtricitabine/Tenofov Alafenam | 85 | $182,398 |
| PifeltroDoravirine | 59 | $101,517 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 19 | $75,070 |
| JulucaDolutegravir/Rilpivirine | 19 | $64,824 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $42,829 |
| PrezistaDarunavir | 11 | $39,588 |
| IsentressRaltegravir Potassium | 14 | $25,827 |
| XareltoRivaroxaban | 21 | $21,764 |
| JardianceEmpagliflozin | 25 | $14,489 |
| TybostCobicistat | 16 | $13,250 |
| VascepaIcosapent Ethyl | 15 | $4,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya, Tybost | $9,282 | $867,973271 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Rukobia, Juluca | $36,698 | $715,362219 claims |
| MerckPifeltro, Isentress | $949 | $127,34473 claims |
| Janssen Scientific Affairs, LLCPrezista | $466 | $39,58811 claims |
| Johnson & JohnsonXarelto | $268 | $21,76421 claims |
| AstraZenecaSymbicort | $149 | $2,79613 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $18 | $24017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Denver
- Ethan LazarusDenver$688K
- Mark DeutchmanDenver$258K
- Flory KreutterDenver$13K
- Khoi NguyenDenver$13K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.